Product Description
AC-1202, also know as Tricaprilin, is being developed by Cerecin for the treatment of patients with Alzheimer's disease. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00142805?term=AC-1202&draw=2&rank=6)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Cerecin
Company Location: Asia Pacific
Company Founding Year: 2001
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Alzheimer Disease
Phase 1: Healthy Volunteers|Alzheimer Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05028114 |
AC-21-025 | P1 |
Terminated |
Alzheimer Disease |
2022-03-18 |
12% |
2023-10-18 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT03635879 |
AX-18-018_PK | P1 |
Withdrawn |
Alzheimer Disease |
2019-04-16 |
14% |
2019-05-30 |
Treatments |
NCT03063645 |
AC-17-014_BE | P1 |
Completed |
Healthy Volunteers |
2017-04-07 |
2019-05-30 |
Treatments |
|
NCT02959710 |
AC-16-013_BE | P1 |
Completed |
Healthy Volunteers |
2017-02-01 |
2019-05-30 |
Treatments |
|
NCT02833012 |
AC-16-012_BE | P1 |
Completed |
Healthy Volunteers |
2016-09-01 |
2019-05-30 |
Treatments |
|
NCT01122329 |
AD | P4 |
Completed |
Alzheimer Disease |
2015-01-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|